Skip to main content

Regions

By Jessica Hagen | 01:39 pm | December 10, 2024
The Series B extension brings the round to $35 million, raising Hyro's total funding to $50 million.
By Anthony Vecchione | 01:32 pm | December 10, 2024
The company will use the funds to enhance its R&D strategy, advance its SEEDIT platform and boost product development.  
By Anthony Vecchione | 10:35 am | December 10, 2024
Sameer Sethi, senior vice president and chief AI and insights officer at Hackensack Meridian Health joined MobiHealthNews to discuss the health system's plans for AI spending in 2025.   
By HIMSS TV | 10:27 am | December 10, 2024
Andre Esteva, CEO and cofounder of Artera, a spin-out of Salesforce, relays how the company's AI tool looks at images of cancer tumors and recommends specific therapies to clinicians.
By HIMSS TV | 06:09 pm | December 09, 2024
It's important that Congress take action on the telehealth and remote patient monitoring extensions from the pandemic that officially expire on December 31, says Tom Leary, senior vice president and head of government relations at HIMSS.
By Jessica Hagen | 05:59 pm | December 09, 2024
The company will use the funds to accelerate the commercialization of its TAPS therapy and enhance the visibility of its offerings among providers and patients.
By Anthony Vecchione | 04:01 pm | December 09, 2024
The partnership will link advanced remote patient monitoring technology with virtual maternity services.  
By Jessica Hagen | 02:25 pm | December 09, 2024
Former HealthTap employees allege that Mohr Davidow Ventures and company leaders stripped them of equity to position the company for a profitable turnaround benefiting MDV.
By HIMSS TV | 12:14 pm | December 09, 2024
Eric Smith, chief digital officer at Memorial Hermann Health System, discusses the health systems' AI governance council and the use of AI in its day-to-day operations - including patient interactions and ambient listening. 
By Anthony Vecchione | 02:36 pm | December 06, 2024
The company will use the funds to expand its commercial growth and clinical-evidence generation.